Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China. [electronic resource]
Producer: 20180725Description: e0195117 p. digitalISSN:- 1932-6203
- Adult
- Antiviral Agents -- administration & dosage
- Carbamates
- China -- epidemiology
- Cohort Studies
- Cost-Benefit Analysis
- Disease Progression
- Female
- Genotype
- Health Care Costs
- Hepatitis C, Chronic -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Interferon-alpha -- administration & dosage
- Isoquinolines -- administration & dosage
- Male
- Markov Chains
- Middle Aged
- Monte Carlo Method
- Polyethylene Glycols -- administration & dosage
- Probability
- Pyrrolidines
- Quality of Life
- Recombinant Proteins -- administration & dosage
- Ribavirin -- administration & dosage
- Sensitivity and Specificity
- Sulfonamides -- administration & dosage
- Treatment Outcome
- Valine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.